this issue:
Tildrakizumab for moderate-to-severe psoriasis
Modifiable risk factors for development of PsA
Real-world treatment patterns with ixekizumab or secukinumab
Long-term safety of systemic medications for psoriasis
Serious infection risk in children with psoriasis on systemic treatment
Drug survival, discontinuation rates and safety profile of secukinumab
Caring for young people with moderate-tosevere psoriasis
Consensus on the definition of a treat-totarget outcome
Please login below to download this issue (PDF)